You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Analytics-Based Platform for Diabetic Retinopathy Care Management
SBC: RETINAL CARE INC Topic: NEIABSTRACT Despite the overefficacy of diabetic retinopathyDRtreatmentit continues to be the leading cause of blindness in working age AmericansOvermillion adults in the US have diabetesOf thesewill develop DR andwill develop vision threatening DRVTDRCurrentlyless than half of all patients with diabetes receive the recommended annual dilated eye exam andof those diagnosed with VTDRonlyundergo timely ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated Intestinal Electrical Stimulation for Diabetes
SBC: TRANSTIMULATION RESEARCH INC Topic: 200Diabetes affects more than 9% of Americans and costs over $300 billion in 2017 in USA. Medical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gain. Bariatric surgery has been proposed for treating diabetic patients with promising outcomes. In this project, we propose a novel method of intestinal electrical stimulation (IES) for treatin ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of an M Protein-Deficient Respiratory Syncytial Virus Vaccine for Aerosolized Vaccination of the Lung
SBC: HEARTLAND VACCINES LLC Topic: NIAIDProject Summary/Abstract Respiratory syncytial virus (RSV) is a major respiratory pathogen in human infants and elderly individuals. RSV infection is the principal cause of hospitalization of infants, and is a leading cause of infant mortality worldwide. In elderly adults, RSV infection accounts for 10-15,000 deaths annually in the US alone. Despite the high impact of RSV, there is presently no li ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)
SBC: PROGENTEC DIAGNOSTICS INC Topic: NIAIDPROJECT SUMMARY ABSTRACTSystemic lupus erythematosusSLEis a multifaceted autoimmune disease characterized by immune dysregulationdisabling symptoms and progressive organ damageRecognition and early treatment to prevent tissue and organ damage is challengingas signs and symptoms of high disease activity and clinical disease flare are captured after their occurrenceDespite clinical instruments of di ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Prevention of arthritis-induced bone erosion by inhibiting osteoclast differentiation by the haloanilide, N-Methyl Dichloropropionaniline
SBC: ExesaLibero Pharma Topic: NIAMSWe are working on a new approach to treating acute arthritis based on a common pathway in the cellular infiltrates that damage bones and jointsInflammatory arthritis disables thousands of people each yearIt occurs in children and adultsafter trauma and infections but most cases are idiopathicMillions of adults live with chronic RAwhich has similar featuresInflammatory arthritis often requires trea ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A novel PPAR-a agonist for treating retinal inflammation and vascular hyper-permeability
SBC: EXCITANT THERAPEUTICS LLC Topic: nPROJECT SUMMARY The aim of this proposal is to develop a small molecule suitable for long term systemic administration to prevent treat DRCurrent standard of care for diabetic retinopathyDRor other ocular diseases with an obvious dysfunctional microvasculature basisrely on treatment options that are inherently challenged with technical limitations and financial constraintsFor examplehigh costrequi ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF INHALED CLOFAZIMINE POWDER AS NOVEL TREATMENT FOR MDR TB FORMULATION AND PRECLINICAL EVALUATION
SBC: Northbound Therapeutics, Inc. Topic: NIAIDNot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of an ADC against Pancreatic Cancer
SBC: COARE BIOTECHNOLOGY, INC. Topic: 102DESCRIPTION provided by applicant Pancreatic ductal adenocarcinoma PDAC is one of the most devastating human cancers It is the fourth leading cause of cancer related deaths in the U S with a year survival rate Despite FDA approved therapeutic regimens and advances in medical and surgical care no significant impact on PDAC patient survival has been observed In an estimated ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of ADC to Target Tumor Stem Cells In Colorectal Cancer
SBC: COARE BIOTECHNOLOGY, INC. Topic: 102DESCRIPTION provided by applicant Colorectal cancer CRC is the third leading cause of cancer related death in the U S Although advances in CRC screening surgical therapies and medical management have improved clinical outcomes there still is a major need to develop better medical therapies for CRC particularly among those with advanced local or metastatic disease The year survival rat ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Novel Therapeutic Antibody for Age-related Macular Degeneration
SBC: Charlesson, LLC Topic: WDESCRIPTION provided by applicant Age related macular degeneration AMD is a common disease of the central retina and remains a leading cause of vision loss and blindness in elderly Americans Currently the standard of care for wet AMD is intravitreal vascular endothelial growth factor VEGF inhibitors However these therapies are not always effective in all patients AMD is a multi factori ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health